233 related articles for article (PubMed ID: 17724476)
1. Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1.
Averous J; Fonseca BD; Proud CG
Oncogene; 2008 Feb; 27(8):1106-13. PubMed ID: 17724476
[TBL] [Abstract][Full Text] [Related]
2. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
Hidalgo M; Rowinsky EK
Oncogene; 2000 Dec; 19(56):6680-6. PubMed ID: 11426655
[TBL] [Abstract][Full Text] [Related]
3. The rapid activation of protein synthesis by growth hormone requires signaling through mTOR.
Hayashi AA; Proud CG
Am J Physiol Endocrinol Metab; 2007 Jun; 292(6):E1647-55. PubMed ID: 17284572
[TBL] [Abstract][Full Text] [Related]
4. Determinants of rapamycin sensitivity in breast cancer cells.
Noh WC; Mondesire WH; Peng J; Jian W; Zhang H; Dong J; Mills GB; Hung MC; Meric-Bernstam F
Clin Cancer Res; 2004 Feb; 10(3):1013-23. PubMed ID: 14871980
[TBL] [Abstract][Full Text] [Related]
5. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition.
Dudkin L; Dilling MB; Cheshire PJ; Harwood FC; Hollingshead M; Arbuck SG; Travis R; Sausville EA; Houghton PJ
Clin Cancer Res; 2001 Jun; 7(6):1758-64. PubMed ID: 11410517
[TBL] [Abstract][Full Text] [Related]
6. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways.
Liu L; Li F; Cardelli JA; Martin KA; Blenis J; Huang S
Oncogene; 2006 Nov; 25(53):7029-40. PubMed ID: 16715128
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-8 signaling promotes translational regulation of cyclin D in androgen-independent prostate cancer cells.
MacManus CF; Pettigrew J; Seaton A; Wilson C; Maxwell PJ; Berlingeri S; Purcell C; McGurk M; Johnston PG; Waugh DJ
Mol Cancer Res; 2007 Jul; 5(7):737-48. PubMed ID: 17606477
[TBL] [Abstract][Full Text] [Related]
8. Rapamycin-induced G1 cell cycle arrest employs both TGF-β and Rb pathways.
Chatterjee A; Mukhopadhyay S; Tung K; Patel D; Foster DA
Cancer Lett; 2015 May; 360(2):134-40. PubMed ID: 25659819
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus-mediated eukaryotic initiation factor 4E binding protein-1 in combination with rapamycin inhibits tumor growth of pancreatic ductal adenocarcinoma in vivo.
Mishra R; Miyamoto M; Yoshioka T; Ishikawa K; Matsumura Y; Shoji Y; Ichinokawa K; Itoh T; Shichinohe T; Hirano S; Kondo S
Int J Oncol; 2009 May; 34(5):1231-40. PubMed ID: 19360336
[TBL] [Abstract][Full Text] [Related]
10. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.
Peponi E; Drakos E; Reyes G; Leventaki V; Rassidakis GZ; Medeiros LJ
Am J Pathol; 2006 Dec; 169(6):2171-80. PubMed ID: 17148679
[TBL] [Abstract][Full Text] [Related]
11. AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis.
Mi W; Ye Q; Liu S; She QB
Oncotarget; 2015 Jun; 6(16):13962-77. PubMed ID: 25961827
[TBL] [Abstract][Full Text] [Related]
12. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.
Gibbons JJ; Abraham RT; Yu K
Semin Oncol; 2009 Dec; 36 Suppl 3():S3-S17. PubMed ID: 19963098
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of MEK/ERK signaling induces apoptosis of acute myelogenous leukemia cells via inhibition of eukaryotic initiation factor 4E-binding protein 1 and down-regulation of Mcl-1.
Nishioka C; Ikezoe T; Yang J; Yokoyama A
Apoptosis; 2010 Jul; 15(7):795-804. PubMed ID: 20221697
[TBL] [Abstract][Full Text] [Related]
14. Overproduction of cyclin D1 is dependent on activated mTORC1 signal in nasopharyngeal carcinoma: implication for therapy.
Huang XM; Dai CB; Mou ZL; Wang LJ; Wen WP; Lin SG; Xu G; Li HB
Cancer Lett; 2009 Jun; 279(1):47-56. PubMed ID: 19203829
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of mammalian target of rapamycin (mTOR) signalling in C2C12 myoblasts prevents myogenic differentiation without affecting the hyperphosphorylation of 4E-BP1.
Willett M; Cowan JL; Vlasak M; Coldwell MJ; Morley SJ
Cell Signal; 2009 Oct; 21(10):1504-12. PubMed ID: 19481146
[TBL] [Abstract][Full Text] [Related]
16. Putative role of the mTOR/4E-BP1 signaling pathway in the carcinogenesis and progression of gastric cardiac adenocarcinoma.
Yang HY; Xue LY; Xing LX; Wang J; Wang JL; Yan X; Zhang XH
Mol Med Rep; 2013 Feb; 7(2):537-42. PubMed ID: 23229050
[TBL] [Abstract][Full Text] [Related]
17. The effect of p-4E-BP1 and p-eIF4E on cell proliferation in a breast cancer model.
Pons B; Peg V; Vázquez-Sánchez MA; López-Vicente L; Argelaguet E; Coch L; Martínez A; Hernández-Losa J; Armengol G; Ramon Y Cajal S
Int J Oncol; 2011 Nov; 39(5):1337-45. PubMed ID: 21750861
[TBL] [Abstract][Full Text] [Related]
18. Icariside II, a natural mTOR inhibitor, disrupts aberrant energy homeostasis via suppressing mTORC1-4E-BP1 axis in sarcoma cells.
Zhang C; Yang L; Geng YD; An FL; Xia YZ; Guo C; Luo JG; Zhang LY; Guo QL; Kong LY
Oncotarget; 2016 May; 7(19):27819-37. PubMed ID: 27056897
[TBL] [Abstract][Full Text] [Related]
19. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.
Zhou X; Tan M; Stone Hawthorne V; Klos KS; Lan KH; Yang Y; Yang W; Smith TL; Shi D; Yu D
Clin Cancer Res; 2004 Oct; 10(20):6779-88. PubMed ID: 15501954
[TBL] [Abstract][Full Text] [Related]
20. Translation control during prolonged mTORC1 inhibition mediated by 4E-BP3.
Tsukumo Y; Alain T; Fonseca BD; Nadon R; Sonenberg N
Nat Commun; 2016 Jun; 7():11776. PubMed ID: 27319316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]